Yanisorn Nanchaipruek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yanisorn Nanchaipruek has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Charussri Leeyaphan
Department of Dermatology, Faculty of Medicine Siriraj Hospital Mahidol University Bangkok Thailand
3 shared publications - Kanokvalai Kulthanan
Department of Dermatology Faculty of Medicine Siriraj Hospital, Mahidol University Bangkok Thailand
2 shared publications - Nuttagarn Jantanapornchai
Department of Dermatology, Faculty of Medicine Siriraj Hospital Mahidol University Bangkok Thailand
2 shared publications - Papapit Tuchinda
Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, THAILAND
2 shared publications Pattriya Jirawattanadon
Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, THAILAND
2 shared publications- Phumithep Phumariyapong
Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, THAILAND
2 shared publications
Latest Publications
- Open Access
The Prevalence of Symptomatic Dermographism: Results of the International UCARE PREVALENCE ‐D Study
Background: The prevalence of symptomatic dermographism ( SD ) in the general population remains unclear. This study aimed to internationally estimate the prevalence of SD and two other dermographic subtypes—physiological red dermographism and simple urticarial dermographism—among adults worldwide. Methods: The PREVALENCE ‐D (Prevalence Estimation of Dermographism) study was the largest international, cross‐sectional, internet‐based investigation conducted by the Urticaria Centers of Reference and Excellence of the Global Allergy and Asthma Excellence Network from 2021 to 2024. A world expert‐designed questionnaire was completed by participants from 28 centers across 19 countries to diagnose SD . Participants were recruited into three age groups (18–24, 25–60, and > 60 years), with ≥ 1000 individuals per group per country. We calculated sex‐ and age‐adjusted prevalence estimates internationally and by country, with 95% confidence intervals. Results: Among 59,543 participants worldwide, those with SD had an adjusted point prevalence of 3.20% (95% confidence interval [ CI ] 2.68%–3.73%) and a lifetime prevalence of 5.94% (95% CI 5.32%–6.56%). The 25–60 years group presented the highest prevalence. Females had higher rates than males, with statistically significant differences across all age groups for both point and lifetime prevalence. Physiological red dermographism had an adjusted point prevalence of 10.02% (95% CI 9.48%–10.55%) and a lifetime prevalence of 33.47% (95% CI 32.01%–34.94%). Simple urticarial dermographism showed an adjusted point prevalence of 1.21% (95% CI 1.08%–1.35%) and a lifetime prevalence of 5.39% (95% CI 4.99%–5.79%). Conclusion: These findings provide comprehensive international estimates of dermographism, particularly SD , and emphasize the need for appropriate healthcare resource allocation and disease recognition.
Open AccessThe Prevalence of Symptomatic Dermographism: Results of the International UCARE PREVALENCE ‐D Study
Background: The prevalence of symptomatic dermographism ( SD ) in the general population remains unclear. This study aimed to internationally estimate the prevalence of SD and two other dermographic subtypes—physiological red dermographism and simple urticarial dermographism—among adults worldwide. Methods: The PREVALENCE ‐D (Prevalence Estimation of Dermographism) study was the largest international, cross‐sectional, internet‐based investigation conducted by the Urticaria Centers of Reference and Excellence of the Global Allergy and Asthma Excellence Network from 2021 to 2024. A world expert‐designed questionnaire was completed by participants from 28 centers across 19 countries to diagnose SD . Participants were recruited into three age groups (18–24, 25–60, and > 60 years), with ≥ 1000 individuals per group per country. We calculated sex‐ and age‐adjusted prevalence estimates internationally and by country, with 95% confidence intervals. Results: Among 59,543 participants worldwide, those with SD had an adjusted point prevalence of 3.20% (95% confidence interval [ CI ] 2.68%–3.73%) and a lifetime prevalence of 5.94% (95% CI 5.32%–6.56%). The 25–60 years group presented the highest prevalence. Females had higher rates than males, with statistically significant differences across all age groups for both point and lifetime prevalence. Physiological red dermographism had an adjusted point prevalence of 10.02% (95% CI 9.48%–10.55%) and a lifetime prevalence of 33.47% (95% CI 32.01%–34.94%). Simple urticarial dermographism showed an adjusted point prevalence of 1.21% (95% CI 1.08%–1.35%) and a lifetime prevalence of 5.39% (95% CI 4.99%–5.79%). Conclusion: These findings provide comprehensive international estimates of dermographism, particularly SD , and emphasize the need for appropriate healthcare resource allocation and disease recognition.
- Open Access
- 1 January 2024
- Published by XMLink in Clinical and Experimental Vaccine Research
- Vol. 13 (4) , 309-314
Clinical presentation, associated factors, and course of cutaneous reaction after the booster dose of COVID-19 vaccination
Jirawattanadon P, et al. Clin Exp Vaccine Res. 2024 Oct;13(4):309-314. https://doi.org/10.7774/cevr.2024.13.4.309
- 1 January 2024
- Published by XMLink in Clinical and Experimental Vaccine Research
- Vol. 13 (4) , 309-314
Open AccessClinical presentation, associated factors, and course of cutaneous reaction after the booster dose of COVID-19 vaccination
Jirawattanadon P, et al. Clin Exp Vaccine Res. 2024 Oct;13(4):309-314. https://doi.org/10.7774/cevr.2024.13.4.309
- Open Access
- 31 December 2023
- Published by Hindawi Limited in Dermatology Research and Practice
- Vol. 2023, 1-8
Herpes Zoster after COVID-19 Infection or Vaccination: A Prospective Cohort Study in a Tertiary Dermatology Clinic
Background. Herpes zoster (HZ) has been observed to occur after COVID-19 infection and vaccination; however, knowledge regarding the demographic data, clinical presentations, and treatment outcomes of HZ is limited. Objective. To compare the demographic data, clinical manifestations, treatments, and outcomes of patients with and without HZ within 14 days of COVID-19 infection or vaccination. Methods. This prospective cohort study involving patients diagnosed with cutaneous HZ was conducted at a dermatology clinic from October 2021 to January 2023. Results. Among a total of 232 patients with HZ, the median age was 62.0 years and 59.1% were female. HZ developed in 23 (9.9%) and four (1.7%) patients after COVID-19 vaccination and infection, respectively. The mean duration from vaccination and the median duration from infection to HZ onset were 5.7 and 8.5 days, respectively. The proportion of female patients was significantly higher in the group of patients with COVID-19 vaccination or infection than in those without such a history ( = 0.035). Patients who developed HZ following the recent COVID-19 infection had a median age of 42.5 years, which was lower than that of the other groups. Dissemination occurred in 8.7% of the patients after COVID-19 vaccination. HZ recurrence was reported in five cases, of which 80% had been vaccinated or infected with COVID-19 during the previous 21 days. All patients had similar durations of antiviral treatment, crust-off time, and duration of neuralgia. Conclusions. HZ after COVID-19 vaccination is more frequently observed in females, while HZ after COVID-19 infection tends to occur in younger patients. Disseminated HZ is more common in patients recently vaccinated against COVID-19. COVID-19 vaccination or infection may trigger recurrent HZ infection.
- 31 December 2023
- Published by Hindawi Limited in Dermatology Research and Practice
- Vol. 2023, 1-8
Open AccessHerpes Zoster after COVID-19 Infection or Vaccination: A Prospective Cohort Study in a Tertiary Dermatology Clinic
Background. Herpes zoster (HZ) has been observed to occur after COVID-19 infection and vaccination; however, knowledge regarding the demographic data, clinical presentations, and treatment outcomes of HZ is limited. Objective. To compare the demographic data, clinical manifestations, treatments, and outcomes of patients with and without HZ within 14 days of COVID-19 infection or vaccination. Methods. This prospective cohort study involving patients diagnosed with cutaneous HZ was conducted at a dermatology clinic from October 2021 to January 2023. Results. Among a total of 232 patients with HZ, the median age was 62.0 years and 59.1% were female. HZ developed in 23 (9.9%) and four (1.7%) patients after COVID-19 vaccination and infection, respectively. The mean duration from vaccination and the median duration from infection to HZ onset were 5.7 and 8.5 days, respectively. The proportion of female patients was significantly higher in the group of patients with COVID-19 vaccination or infection than in those without such a history ( = 0.035). Patients who developed HZ following the recent COVID-19 infection had a median age of 42.5 years, which was lower than that of the other groups. Dissemination occurred in 8.7% of the patients after COVID-19 vaccination. HZ recurrence was reported in five cases, of which 80% had been vaccinated or infected with COVID-19 during the previous 21 days. All patients had similar durations of antiviral treatment, crust-off time, and duration of neuralgia. Conclusions. HZ after COVID-19 vaccination is more frequently observed in females, while HZ after COVID-19 infection tends to occur in younger patients. Disseminated HZ is more common in patients recently vaccinated against COVID-19. COVID-19 vaccination or infection may trigger recurrent HZ infection.
- Open Access
- 2 March 2023
- Published by Wiley in Journal of Oral Rehabilitation
- Vol. 50 (5) , 343-350
Duration of bite force reduction following a single injection of botulinum toxin in the masseter muscle bilaterally: A one‐year non‐randomized trial
Background: Previous studies concerning the effect of botulinum toxin in masseter muscle have mainly reported effects observed through inspection of facial features or differences in pain levels. One systematic review of studies utilizing objective measurements reported that long‐term muscular effect of botulinum neurotoxin injections into masseter muscle was inconclusive.Objective: To evaluate the duration of reduced maximal voluntary bite force (MVBF) after botulinum toxin intervention.Methods: The intervention group was comprised of individuals seeking aesthetic treatment for masseter reduction (n = 20), the reference group (n = 12) comprised of individuals with no intervention. Intervention through 25 units of Xeomin® (Merz Pharma GmbH & Co KGaA, Frankfurt am Main, Germany) botulinum neurotoxin type A injected into the masseter muscles bilaterally (totalling 50 units). A reference group did not receive any intervention. MVBF was measured in Newtons using a strain gauge meter at the incisors and first molars. MVBF was measured at baseline, at 4 weeks, 3 months, 6 months, and after 1 year.Results: Both groups were similar in terms of bite force, sex and age at baseline. MVBF remained similar compared to baseline in the reference group. At 3 months, a significant reduction at all measurement points was observed in the intervention group; at 6 months, this reduction was no longer significant.Conclusion: A single intervention of 50 units of botulinum neurotoxin results in a reversible MVBF reduction of at least 3 months, although a visually discernable reduction may be more long‐lasting.
- 2 March 2023
- Published by Wiley in Journal of Oral Rehabilitation
- Vol. 50 (5) , 343-350
Open AccessDuration of bite force reduction following a single injection of botulinum toxin in the masseter muscle bilaterally: A one‐year non‐randomized trial
Background: Previous studies concerning the effect of botulinum toxin in masseter muscle have mainly reported effects observed through inspection of facial features or differences in pain levels. One systematic review of studies utilizing objective measurements reported that long‐term muscular effect of botulinum neurotoxin injections into masseter muscle was inconclusive.Objective: To evaluate the duration of reduced maximal voluntary bite force (MVBF) after botulinum toxin intervention.Methods: The intervention group was comprised of individuals seeking aesthetic treatment for masseter reduction (n = 20), the reference group (n = 12) comprised of individuals with no intervention. Intervention through 25 units of Xeomin® (Merz Pharma GmbH & Co KGaA, Frankfurt am Main, Germany) botulinum neurotoxin type A injected into the masseter muscles bilaterally (totalling 50 units). A reference group did not receive any intervention. MVBF was measured in Newtons using a strain gauge meter at the incisors and first molars. MVBF was measured at baseline, at 4 weeks, 3 months, 6 months, and after 1 year.Results: Both groups were similar in terms of bite force, sex and age at baseline. MVBF remained similar compared to baseline in the reference group. At 3 months, a significant reduction at all measurement points was observed in the intervention group; at 6 months, this reduction was no longer significant.Conclusion: A single intervention of 50 units of botulinum neurotoxin results in a reversible MVBF reduction of at least 3 months, although a visually discernable reduction may be more long‐lasting.
- 25 August 2022
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 33 (11) , 963-969
Characteristics of HIV/sexually transmitted infections among men who have sex with men and women in Bangkok, Thailand
Background: Men who have sex with men (MSM) are a key HIV target population in Thailand. An important subgroup is men who have sex with men and women (MSMW) as they can sexually transmit infections between individuals with different gender identities. This study compared the sexually transmitted infection risk behavior of different types of men in Thailand. Methods: We retrospectively reviewed the medical records of 839 consecutive male patients who visited an STI clinic in Bangkok, Thailand, between 2014 and 2020. Results: Men who have sex with women only (MSWO) predominated (58.0%), followed by men who have sex with men only (MSMO, 32.2%) and MSMW (9.8%). MSMW and MSMO shared similar sexual risk behaviors, such as significantly higher median numbers of sex partners (10 and 8, respectively) than MSWO (5; Kruskal–Wallis, p < 0.001). MSMW had the highest prevalence of concurrent sexual partnerships (91.4%), significantly different from MSWO (61.2%) and MSMO (76.7%; chi-squared, p < 0.001). HIV and syphilis prevalence was significantly higher for MSMO (48.9% and 51.1%) and MSMW (42.7% and 48.8%) than MSWO (12.3% and 20.9%; chi-squared, p < 0.001). Conclusions: MSMW exhibited similar sexual risk behavior and high HIV/STI prevalence comparable to MSMO.
- 25 August 2022
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 33 (11) , 963-969
Characteristics of HIV/sexually transmitted infections among men who have sex with men and women in Bangkok, Thailand
Background: Men who have sex with men (MSM) are a key HIV target population in Thailand. An important subgroup is men who have sex with men and women (MSMW) as they can sexually transmit infections between individuals with different gender identities. This study compared the sexually transmitted infection risk behavior of different types of men in Thailand. Methods: We retrospectively reviewed the medical records of 839 consecutive male patients who visited an STI clinic in Bangkok, Thailand, between 2014 and 2020. Results: Men who have sex with women only (MSWO) predominated (58.0%), followed by men who have sex with men only (MSMO, 32.2%) and MSMW (9.8%). MSMW and MSMO shared similar sexual risk behaviors, such as significantly higher median numbers of sex partners (10 and 8, respectively) than MSWO (5; Kruskal–Wallis, p < 0.001). MSMW had the highest prevalence of concurrent sexual partnerships (91.4%), significantly different from MSWO (61.2%) and MSMO (76.7%; chi-squared, p < 0.001). HIV and syphilis prevalence was significantly higher for MSMO (48.9% and 51.1%) and MSMW (42.7% and 48.8%) than MSWO (12.3% and 20.9%; chi-squared, p < 0.001). Conclusions: MSMW exhibited similar sexual risk behavior and high HIV/STI prevalence comparable to MSMO.
- Open Access
- 23 June 2022
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2022, 1-6
Efficacy and Safety of Clinacanthus nutans Lindau Cream vs. Podophyllin for the Treatment of Adults with Condyloma Acuminata
Human papillomavirus (HPV) infection causes condyloma acuminata (CA). Podophyllin is the standard treatment. Clinacanthus nutans Lindau (C. nutans), a medicinal plant, has potent anti-inflammatory and antiviral effects. C. nutans cream is widely used in Thailand to treat the herpes simplex virus. We proposed that C. nutans might also induce CA clearance. There are no studies of C. nutans treatment of CA. This randomized controlled trial at Siriraj Hospital, Thailand, was conducted between January 2018 and December 2019. CA samples were obtained from 10 men with at least two CAs 1 centimeter apart. Each wart was randomized to a 4-week treatment with either C. nutans or podophyllin. The participants were 24 to 72 years old. Most HPV types were low-risk HPVs (HPV 11, HPV 6). Median CA clearance with podophyllin was a 97 CA clearance with podophyllin and 82 with C. nutans. C. nutans may be an alternative treatment for CA.
- 23 June 2022
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2022, 1-6
Open AccessEfficacy and Safety of Clinacanthus nutans Lindau Cream vs. Podophyllin for the Treatment of Adults with Condyloma Acuminata
Human papillomavirus (HPV) infection causes condyloma acuminata (CA). Podophyllin is the standard treatment. Clinacanthus nutans Lindau (C. nutans), a medicinal plant, has potent anti-inflammatory and antiviral effects. C. nutans cream is widely used in Thailand to treat the herpes simplex virus. We proposed that C. nutans might also induce CA clearance. There are no studies of C. nutans treatment of CA. This randomized controlled trial at Siriraj Hospital, Thailand, was conducted between January 2018 and December 2019. CA samples were obtained from 10 men with at least two CAs 1 centimeter apart. Each wart was randomized to a 4-week treatment with either C. nutans or podophyllin. The participants were 24 to 72 years old. Most HPV types were low-risk HPVs (HPV 11, HPV 6). Median CA clearance with podophyllin was a 97 CA clearance with podophyllin and 82 with C. nutans. C. nutans may be an alternative treatment for CA.
- 27 May 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 49 (9) , 879-886
Therapeutic outcomes and prognostic factors in patients with hypertrophic herpes simplex infection treated with imiquimod: A systematic review and meta‐analysis of individual patient data from case reports and case series
Hypertrophic herpes simplex (HHS) often has atypical presentations, such as a hypertrophic mass or ulcers, with chronic courses. This situation poses a diagnostic challenge and results in delayed treatment. Imiquimod was used as a treatment for HHS by several studies, but the therapeutic outcomes varied. This systematic review and meta‐analysis of individual patient data was conducted to investigate the therapeutic outcomes and prognostic factors of imiquimod treatment for patients with HHS. Biomedical databases (Embase, PubMed, Medline, Cochrane Controlled Trials Register, and ClinicalTrials.gov) were searched for all types of clinical studies reporting the complete cure rate and the time to complete response to imiquimod therapy between 1926 and 2021. Quantitative analysis of individual patient data was performed using multivariable flexible parametric survival regression with cluster variance correction. A total of 12 019 articles were identified and screened for eligibility. Twenty‐five studies (21 case reports and four case series) with a combined total of 42 patients were included. The complete cure rate for imiquimod treatment was estimated at 88.1%. The median time to complete response was 60 days (95% confidence interval 35–70). Combined treatment, male sex, and an age less than 50 years were identified as significant prognostic factors for a shorter time to complete cure. A severe local reaction was reported in 2.3%. Imiquimod therapy has high effectiveness and safety in curing HHS. Patients who were male or younger than 50 years or whose treatments were combined with thymidine kinase‐dependent antivirals had the best prognoses and were more likely to respond to treatment.
- 27 May 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 49 (9) , 879-886
Therapeutic outcomes and prognostic factors in patients with hypertrophic herpes simplex infection treated with imiquimod: A systematic review and meta‐analysis of individual patient data from case reports and case series
Hypertrophic herpes simplex (HHS) often has atypical presentations, such as a hypertrophic mass or ulcers, with chronic courses. This situation poses a diagnostic challenge and results in delayed treatment. Imiquimod was used as a treatment for HHS by several studies, but the therapeutic outcomes varied. This systematic review and meta‐analysis of individual patient data was conducted to investigate the therapeutic outcomes and prognostic factors of imiquimod treatment for patients with HHS. Biomedical databases (Embase, PubMed, Medline, Cochrane Controlled Trials Register, and ClinicalTrials.gov) were searched for all types of clinical studies reporting the complete cure rate and the time to complete response to imiquimod therapy between 1926 and 2021. Quantitative analysis of individual patient data was performed using multivariable flexible parametric survival regression with cluster variance correction. A total of 12 019 articles were identified and screened for eligibility. Twenty‐five studies (21 case reports and four case series) with a combined total of 42 patients were included. The complete cure rate for imiquimod treatment was estimated at 88.1%. The median time to complete response was 60 days (95% confidence interval 35–70). Combined treatment, male sex, and an age less than 50 years were identified as significant prognostic factors for a shorter time to complete cure. A severe local reaction was reported in 2.3%. Imiquimod therapy has high effectiveness and safety in curing HHS. Patients who were male or younger than 50 years or whose treatments were combined with thymidine kinase‐dependent antivirals had the best prognoses and were more likely to respond to treatment.
- 19 January 2022
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 48 (5) , 591-593
Efficacy and Safety of Electrical Multidirectional Stimulation for Abdominal Contouring in Thai Subjects With Normal Body Mass Index
An abstract is unavailable. This article is available as a PDF only.
- 19 January 2022
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 48 (5) , 591-593
Efficacy and Safety of Electrical Multidirectional Stimulation for Abdominal Contouring in Thai Subjects With Normal Body Mass Index
An abstract is unavailable. This article is available as a PDF only.